S-1: SS Innovations Files S-1 for $50M Offering Amid Strong Growth

SS Innovations International, Inc. filed an S-1 registration statement for a $50 million common stock offering, highlighting significant revenue and installation growth for its SSi Mantra surgical robotic system, despite ongoing net losses and a 'going concern' warning.

Summary

• SS Innovations International, Inc. is offering 11,286,681 shares of common stock, with an underwriters' option for an additional 1,693,002 shares, at an assumed public offering price of $4.43 per share.
• The company expects net proceeds of approximately $45.8 million (or $52.8 million if the over-allotment option is fully exercised) for working capital, manufacturing expansion, global clinical trials, and regional marketing offices.
• Preliminary unaudited Q4 2025 revenue is expected to be $15.0 million, an 85% increase from $8.1 million in Q4 2024.
• Preliminary unaudited full-year 2025 revenue is expected to be $43.0 million, a 108% increase from $20.6 million in 2024.
• SSi Mantra installations totaled 37 in Q4 2025 (up 68% from 22 in Q4 2024) and 103 for the full year 2025 (up 119% from 47 in 2024).
• The cumulative installed base of SSi Mantra systems reached 168 as of December 31, 2025, a 158% increase from 65 as of December 31, 2024.
• The SSi Mantra system has been used in over 7,800 surgical procedures across 153 hospitals in 10 countries as of December 31, 2025, with no device-related adverse events.
• The latest generation, SSi Mantra 3, introduced in India in November 2024, includes telesurgery and tele-proctoring capabilities, with over 120 telesurgeries performed to date, including inter-continental cardiac surgery.
• The company has incurred net losses since its inception, with $9.66 million for the nine months ended September 30, 2025, and $19.15 million for the year ended December 31, 2024.
• Management has reported that disclosure controls and procedures and internal control over financial reporting were not effective as of September 30, 2025, due to issues with GAAP application, lack of written documentation, and insufficient segregation of duties.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing with a neutral-to-cautious sentiment. While the company demonstrates impressive revenue and installation growth, indicating strong market traction for its product, the persistent 'going concern' warning and internal control weaknesses introduce significant financial uncertainty. The capital raise is crucial for continued operations and expansion, but the inherent dilution and regulatory approval uncertainties temper enthusiasm.

Positives

• Significant revenue growth: 85% increase in Q4 2025 revenue and 108% increase in full-year 2025 revenue compared to prior periods.
• Strong product adoption: 119% increase in SSi Mantra installations for full-year 2025, reaching a cumulative installed base of 168 systems across 10 countries.
• Clinical validation and safety: Over 7,800 surgical procedures performed across 9 specialties with no device-related adverse events, demonstrating safety and efficacy.
• Technological innovation: Introduction of SSi Mantra 3 with telesurgery and tele-proctoring capabilities, including successful inter-continental robotic cardiac telesurgery.
• Market expansion potential: Regulatory approvals in 10 countries and ability to market in 50 non-FDA/EU countries without further approval, with minimal registration required in an additional 79 countries.
• Cost-effectiveness: The SSi Mantra is designed to be an affordable surgical robotic system, breaking down barriers to access in underserved regions.
• Strong leadership: Led by Dr. Sudhir P. Srivastava, an internationally recognized robotic cardiothoracic surgeon with extensive experience.
• Positive industry trends: Growing demand for minimally invasive surgery, increasing health insurance penetration in India, and medical value travel support market growth.

Negatives

• Recurring losses: The company has incurred losses since inception and expects to continue incurring operating losses and negative cash flow for the foreseeable future.
• Going concern doubt: The company's recurring losses and negative cash flows raise substantial doubt about its ability to continue as a going concern.
• Internal control weaknesses: Management reported ineffective disclosure controls and internal control over financial reporting, citing issues with GAAP application, lack of documentation, and insufficient segregation of duties.
• Significant dilution: Investors in this offering will experience immediate and substantial dilution of $4.02 per share in book value.
• Reliance on related party financing: The company has been dependent on its principal shareholder, Dr. Sudhir Srivastava (through Sushruta), for substantial financing.
• Regulatory uncertainty: No assurance of securing FDA approval and EU certification for the SSi Mantra in 2026, which is crucial for international market expansion.
• High competition: Operates in a highly competitive global medical device and surgical robotics market with well-capitalized competitors having greater resources.
• Product liability risks: The use of surgical robotic systems exposes the company to significant product liability and negligence risks, with potentially inadequate insurance coverage.

Risks

• We are an early-stage revenue company with a limited operating history and may never achieve or maintain profitability.
• Significant additional financing will be required to expand marketing, obtain regulatory approvals, and develop product enhancements; failure to obtain capital could delay or terminate activities.
• If our SSi Mantra and related devices do not achieve market acceptance in India and abroad, we will not be able to generate necessary revenue.
• Customers may resist the effort required for training on the SSi Mantra, leading to lost revenue.
• The SSi Mantra and related devices have not been approved for marketing in the U.S. or the EU, and failure to obtain and maintain necessary international regulatory approvals or certifications will limit sales.
• Defects discovered in our surgical robotic system could lead to unforeseen costs, lost sales, and reputational damage.
• The use of our surgical robotic systems exposes us to significant product liability and negligence risks, with potentially inadequate or unavailable insurance coverage.
• Manufacturing problems or delays could result in lost revenue.
• Reliance on overseas suppliers for components poses risks of supply disruptions.
• Failure to expand sales, marketing, and clinical/technical support teams could impair profitability.
• Our markets are highly competitive, with many competitors having greater experience and financial resources.
• Loss of key personnel or inability to attract and retain additional personnel could harm our ability to compete.
• Substantial portions of our operations in India expose us to various risks, including intellectual property protection, regulatory changes, tariffs, and foreign currency fluctuations.
• Difficulty in enforcing judgments obtained in the U.S. against the company or its directors/executive officers residing in India.
• Hospitals' inability to obtain coverage and reimbursement for procedures using our systems, or insufficient reimbursement, could hinder sales.
• Tariff policies, particularly under the Trump administration, could hamper our ability to import and market surgical robotic systems in the U.S.
• Our business is subject to complex and evolving laws and regulations regarding data privacy, data protection, artificial intelligence, and responsible use of data, including GDPR and HIPAA.
• Inability to protect intellectual property rights from third parties could harm our ability to compete.
• Third parties may assert infringement claims against our systems, leading to costly disputes and potential sales prohibitions.
• Our management has reported ineffective disclosure controls and internal control over financial reporting, which could cause financial reporting to be unreliable.
• Our Chairman and CEO, Dr. Sudhir Srivastava, holds approximately 58.35% of the combined voting power, giving him control over the company and potentially limiting minority shareholders' influence.
• The offering price is not an indication of fair value, and FINRA sales practice requirements may limit shareholders' ability to buy and sell our securities.

Future Outlook

The company anticipates receiving EU and U.S. regulatory approvals for the SSi Mantra in the first half of 2026, though there is no assurance of when or if these will be secured. It expects to continue expending substantial resources on expanded marketing, regulatory approvals, and product enhancements. The company believes the net proceeds from this offering, combined with existing cash and anticipated revenues, will fund operations for at least 24 months, but acknowledges this estimate is based on assumptions that may prove wrong.

Management Comments

• "With the SSi Mantra, we are breaking down barriers and accelerating access to surgical robotics technologies in underserved regions of the world." Dr. Sudhir P Srivastava, Founder, Chairman and Chief Executive Officer.
• "The SSi Mantra marks the realization of Dr. Srivastavas vision to develop and commercialize a surgical robotic system which would facilitate making robotic surgery affordable and accessible to a global population." Company statement regarding Dr. Srivastava's vision.
• "We believe that we will be able to secure FDA approval and EU certification in 2026. However, there can be no assurance as to when or if we will secure such regulatory approvals." Company statement on regulatory timelines.
• "Management recognizes that the Company must obtain additional resources to successfully implement its business plans." Company statement on funding needs.
• "While management of the Company believes that it will be successful in its capital formation and planned expansion of its operating activities, there can be no assurance that the Company will be able to raise additional equity capital or be successful in generating additional revenues and ultimately achieving profitability." Company statement on future funding and profitability.

Industry Context

StockSavvy.ai notes that SS Innovations is positioning itself in the rapidly growing global surgical robotics market, projected to reach $27.14 billion by 2030. The company's focus on affordability and accessibility, particularly in underserved markets like India, aligns with macro healthcare trends of increasing demand, technology adoption, and health insurance penetration in emerging economies. Its emphasis on telesurgery and tele-proctoring also taps into the broader digital health and remote care trends, which are becoming increasingly relevant for surgeon training and expanding access to specialized procedures. However, the market remains highly competitive, dominated by established players with significantly greater resources, posing a challenge for SS Innovations' global expansion.

Comparison to Industry Standards

• SS Innovations' SSi Mantra system is designed to be an 'advanced, next-generation and affordable' alternative to existing systems, aiming to democratize access to surgical robotics, particularly in contrast to the high costs and steep learning curves of current generation systems.
• The company competes with major players like Intuitive Surgical, Inc. (maker of the da Vinci system), Johnson & Johnson, and Medtronic plc, which have significantly longer operating histories and greater financial resources.
• SSi Mantra's clinical validation for over 100 different types of surgical procedures without device-related adverse events demonstrates a strong safety profile, comparable to the rigorous standards expected in the medical device industry.
• The successful performance of inter-continental robotic cardiac telesurgery (Strasbourg, France to Indore, India, over 4,000 miles) and pediatric pyeloplasty telesurgery highlights a unique capability that differentiates SSi Mantra in the remote surgery and tele-mentoring space, potentially surpassing the current remote capabilities of some competitors.
• The development of the SSi Robotic Stapler, which would make SS Innovations the second company globally with a robotic stapler compatible with its platform, indicates a strategic move to match or exceed offerings from leading competitors in instrument breadth.

Management Changes

Corporate Governance

Legal Proceedings

• A dispute with Quinn Emmanuel Urquhart & Sullivan LLP over legal fees from 2014, where a judgment of $296,000 plus interest was entered against the Company and Barry F. Cohen in November 2025. Mr. Cohen has agreed to fully indemnify the Company for any related damages and costs.
• Litigation commenced in the Bahamas in April 2024 by an ex-shareholder of Otto Pvt Ltd (an indirect wholly-owned subsidiary) seeking confirmation of a 9% interest. The plaintiff failed to pay consideration, and the shareholding was cancelled in July 2022. Dr. Sudhir Srivastava and Otto have filed an action to confirm the cancellation. An interim order maintains the status quo of the shares and Otto's assets. Dr. Srivastava has indemnified the Company for any claims related to this litigation or his ventures prior to the April 2023 merger.

Related Party Transactions

• On April 15, 2023, the Company executed a Convertible Promissory Note (Line of Credit Note) with Sushruta Pvt Ltd (Dr. Sudhir Srivastava's holding company) for up to $20,000,000 in advances, convertible at $0.74 per share. $16,980,000 in advances were converted into 22,945,945 shares in 2023.
• In February 2024, Sushruta subscribed for a $1,000,000 7% Convertible One-Year Promissory Note (Bridge Note), which was repaid upon maturity in February 2025.
• In April, July, October, and November 2024, Sushruta provided $2,000,000, $500,000, $500,000, and $500,000 respectively, through 7% One-Year Promissory Notes, all repaid in February 2025.
• From December 2024 to March 2025, Dr. Sudhir Srivastava, through Sushruta, provided $30,000,000 in financing via One-Year 7% Convertible Promissory Notes, convertible at $1.38 per share. All these notes, totaling $30,000,000 principal plus $164,548 interest, were converted into 21,858,368 shares of common stock by March 31, 2025.
• Dr. Frederic Moll, a director, converted $3,049,364 (principal and interest) of convertible notes into 3,767,933 shares of common stock on April 14, 2023, as part of interim financing.
• The company has issued stock options and stock awards to executive officers and directors, including Dr. Sudhir Srivastava, Dr. Vishwajyoti P. Srivastava, and Barry F. Cohen, as detailed in the Executive Compensation tables.
• Barry F. Cohen has agreed to fully indemnify the Company for any damages and costs incurred in connection with the Quinn Emmanuel legal action.
• Dr. Sudhir Srivastava has agreed to fully indemnify the Company for any claims, damages, and costs incurred in connection with the Otto Pvt Ltd litigation or his ventures prior to the April 2023 merger.

Stakeholder Impact

• Shareholders: Existing shareholders will experience immediate and substantial dilution from the offering. The concentration of voting power with Dr. Sudhir Srivastava (58.35%) limits minority shareholder influence. The 'going concern' warning poses a significant risk to investment value.
• Employees: The company's growth and expansion plans could lead to increased employment opportunities. Stock compensation plans are in place to incentivize employees, but the 'going concern' status could impact job security if funding is not sustained.
• Customers (Hospitals/Surgeons): The SSi Mantra aims to provide affordable and accessible robotic surgery, potentially benefiting hospitals and patients in underserved regions. Continued product development and support infrastructure are crucial for customer satisfaction and adoption.
• Suppliers: The company relies heavily on overseas suppliers for components. Disruptions or changes in supply chain could impact manufacturing and delivery, affecting supplier relationships.
• Creditors (HDFC Bank): The company's bank overdraft facility is secured by substantially all operating assets in India and personal guarantees from Dr. Sudhir Prem Srivastava and Dr. Vishwajyoti P Srivastava, indicating a high level of risk for the lender in case of default.

Next Steps

• Finalize and audit preliminary Q4 and full-year 2025 financial and operating results.
• Complete the public offering of common stock to raise approximately $45.8 million to $52.8 million.
• Expand manufacturing capacity through installation of additional machinery and equipment.
• Conduct global clinical trials to meet various regulatory requirements.
• Lease additional office and manufacturing space.
• Establish regional marketing offices.
• Secure FDA approval and EU certification for the SSi Mantra, anticipated in the first half of 2026.
• Continue developing and enhancing SSi Mantra technology and products, including NADI, SSi Multi-Fire Clip Applier, SSi Robotic Stapler, and SSi Maya digital platform.
• Implement a new equity incentive plan following the completion of this offering.
• Address and remediate identified material weaknesses in disclosure controls and internal control over financial reporting, including enhancing review processes, engaging external experts, and implementing a cloud-based ERP system.
• Continue to pursue regulatory approvals in additional international markets beyond the current 10 countries.

Key Dates

Recommendation

The company demonstrates impressive growth in revenue and system installations, particularly in emerging markets, and is making strides in technological innovation like telesurgery. However, the persistent 'going concern' warning, coupled with a history of net losses and identified material weaknesses in internal controls, presents significant financial risks. While the capital raise from this S-1 offering is crucial for funding operations and expansion, the immediate and substantial dilution for new investors, along with the uncertainty of key regulatory approvals (FDA, EU), suggests a cautious approach. A seasoned investor would likely 'hold' to monitor the effective remediation of internal control issues, the successful securing of international regulatory approvals, and the company's path to sustained profitability before considering further investment, despite the promising growth trajectory.

Keywords

Surgical Robotics, Medical Devices, SSi Mantra, Robotic Surgery, Healthcare Technology, Minimally Invasive Surgery, Telesurgery, Tele-proctoring, India Healthcare, FDA Approval, CE Certification, IPO, S-1 Filing, Growth Company